May 24, 2023
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
May 16, 2023
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
May 15, 2023
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
May 09, 2023
Immutep to Participate in the JMP Securities Life Sciences Conference
